Dipeptide Ingredients TRIZ Cases
- Antibody Stabilization with Dipeptides in Intestinal Fluid
Dipeptides stabilize antibodies against protease degradation in intestinal fluid, enabling oral delivery.
- Nonfucosylated Anti-CD70 Antibody Selective Depletion
Nonfucosylated anti-CD70 antibodies deplete cancer cells via enhanced ADCC activity.
- RAS(ON) Inhibitor Targets Active GTP-Bound State to Block Resistance
Targeting the active GTP-bound state prevents resistance mutations at Y96, H95, and R68 that typically render standard RAS(OFF) inhibitors ineffective.
- NEO-201 Monoclonal Antibody Targeting Carcinoma Antigens
A humanized IgG1 monoclonal antibody binds to carcinoma antigens and mediates cytotoxicity against tumor cells.
- Anti-CD38 Antibody Subcutaneous Formulation for Multiple Myeloma
Subcutaneous anti-CD38 antibodies address high toxicity and inconvenient intravenous administration in multiple myeloma therapy.
- Proteasome Inhibitors for HIV Latent Reservoir Elimination
Proteasome inhibitors accumulate pro-apoptotic proteins in reactivated HIV cells to eliminate the latent reservoir.
- Retinylamine Derivatives for Ocular Disorder Treatment
Retinylamine derivatives conjugated with amino acids sequester toxic all-trans-retinal to preserve retinal structure.
- Loperamide and Proteasome Inhibitor Combination for Solid Cancer
Combining loperamide with proteasome inhibitors overcomes solid tumor resistance, reducing side effects while maintaining therapeutic impact.
- Aldehyde Sequestering Agents for Hangover Symptom Reduction
Cysteine derivatives form cyclic thiazolidines with acetaldehyde, resolving blood aldehyde buildup and Asian flushing syndrome.
- Dipeptide TGF-beta Inhibitors for Selective Cancer Therapy
Dipeptide compounds inhibit TGF-beta activity with enhanced plasma stability, resolving adverse effects from non-specific inhibition.
- Sulfomaleimide Linker Stability in Antibody-Drug Conjugates
A sulfomaleimide linker covalently attaches drugs to antibodies via irreversible bonds.
- PROTAC Small Molecules for E3 Ligase Degradation
Segmented PROTAC molecules bridge E3 ligases to induce proteasomal degradation, reducing inhibitor concentration and off-target effects.
- Phenylalanine Dipeptide Derivatives for Hepatitis B Treatment
Modified phenylalanine dipeptides reduce toxic side effects while effectively treating hepatitis B and HIV infections.
- Genetic Diagnosis and Treatment of Coronavirus Infections
Analyzes patient SNPs to tailor RAAS pathway pharmaceuticals, resolving contradictions in ACE2 modulation for pre- and post-infection scenarios.
- CD19 Binding Agents for B-Cell Malignancy Treatment
CD19 binding agents deplete malignant B-cells, reducing relapse rates and improving survival outcomes.